Raymond James Financial
ALGS icon

Raymond James Financial’s Aligos Therapeutics ALGS Stock Holding History

Raymond James Financial’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$3.6K – 5010
2025
Q2 		$3.6K Buy
+500
New +$2.99K ﹤0.01% 6263

Other funds holding ALGS

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Raymond James Financial's ALGS Position: Q3 2025 in Review

Raymond James Financial sold out of Aligos Therapeutics (ALGS) in Q3 2025, closing a stake of 500 shares — an estimated $3.6K sold.

Raymond James Financial first reported a position in ALGS in Q2 2025 and held it in 1 quarter. The position peaked at $3.6K in Q2 2025. 33 funds tracked by Wall St. Rank hold ALGS as of Q3 2025.

  • Raymond James Financial reported no remaining Aligos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 500 Aligos Therapeutics shares in Q3 2025, an estimated $3.6K.
  • Raymond James Financial first reported a position in Aligos Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Aligos Therapeutics position peaked at $3.6K in Q2 2025.
  • 33 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.